CoChat
Cited by 196

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia

Open access
Ganesan, Prasanth, Sagar, Tenali Gnana, Dubashi, Biswajit, Rajendranath, Rejiv, Kannan, Krishnarathinam, Cyriac, Sanju, Nandennavar, Manjunath · 2011 · American Journal of Hematology

Abstract

There is limited data on the impact of treatment interruptions due to nonadherence in patients with chronic phase chronic myeloid leukemia (CP‐CML) treated with Imatinib. We looked at factors (including adherence to therapy) affecting the outcome in a large cohort of patients with CP‐CML. All the 516 patients received Imatinib free‐of‐cost through a company sponsored scheme, which mandated regular three monthly visits for drug procurement. Data regarding the disease characteristics, adherence to treatment and outcomes, were obtained from patients records. Unwarranted interruption of treatment for more than 1 week was defined as nonadherence. With a median follow‐up of 39 months, the estimated 5‐year event free survival (EFS) was 70.8% (95%, CI = 63.3–78.3). Nearly one‐third of the patients (29.6%) were found to be nonadherent at some point during their treatment. On univariate analysis, the factors adversely affecting the EFS were prolonged symptom duration before diagnosis, treatment with hydroxyurea for more than 1 month before start of Imatinib, and nonadherence to therapy. Only nonadherence was significant in multivariate analysis (HR1.6; P = 0.048). The 5‐year EFS in adherent and nonadherent patients was 76.7% and 59.8% respectively (P = 0.011, log rank test). Nonadherent patients were less likely to achieve complete cytogenetic responses (26% versus 44%; P = 0.004; χ 2 test) at any point. A significant proportion of patients with CP‐CML have drug interruptions due to nonadherence during therapy and this compromises the EFS. Adherence to therapy must be included as an important evaluation parameter in all future studies of CML. Am. J. Hematol. 2011. © 2011 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.22019

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 196

Metadata

Authors
Ganesan, P., Sagar, T. G., Dubashi, B., Rajendranath, R., Kannan, K., Cyriac, S., & Nandennavar, M.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2011-04-27
Volume
86
Issue
6
Pages
471-474
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W1991181074
Cited by
196
References
2
FWCI
8.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. https://app.cochat.ai/papers/10.1002/ajh.22019
The paper
Ganesan, P., Sagar, T. G., Dubashi, B., Rajendranath, R., Kannan, K., Cyriac, S., & Nandennavar, M. (2011). Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.22019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.